Skip to main content
MoneyGlobe

Japan Equities

Japan Stock Research

Company-specific research built from earnings releases and investor-relations materials. Each article separates verified facts, conditions that could support the stock, opposing evidence and unavailable real-time data.

Company Research

10 articles
  1. Advantest · 6857 Advantest (6857) Stock: AI Chip Test Demand, Orders and Customer Concentration Assess Advantest through AI and HBM test demand, orders, capacity, margins, inventory and customer concentration ahead of first-quarter results.
  2. Hitachi · 6501 Hitachi (6501) Stock: Lumada, Power Grids, Backlog and Margin Quality Assess Hitachi through Lumada, Hitachi Energy, rail projects, backlog conversion, adjusted EBITA margins and core free cash flow.
  3. Honda Motor · 7267 Honda (7267) Stock: Tariffs, EV Restructuring and Motorcycle Earnings Assess Honda through U.S. tariffs, motorcycle profitability, automotive restructuring, EV investment, Astemo consolidation and FX.
  4. Sumitomo Mitsui Financial Group · 8316 SMFG (8316) Stock: Higher Rates, Card Earnings and Credit Costs Assess Sumitomo Mitsui Financial Group through loan spreads, deposit costs, card payments, credit costs, CET1 capital and shareholder returns.
  5. KDDI · 9433 KDDI (9433) Stock: Telecom Earnings, Lawson Integration and Capital Spending Assess KDDI through telecom ARPU, churn, finance, enterprise DX, Lawson integration, data centers, capex and debt.
  6. Mitsubishi Corporation · 8058 Mitsubishi Corporation (8058) Stock: LNG, Copper, Buybacks and Non-Resource Profit Assess Mitsubishi Corporation through LNG and copper exposure, non-resource earnings, investment discipline, cash flow and shareholder returns.
  7. Recruit Holdings · 6098 Recruit Holdings (6098) Stock: Indeed Demand, Hiring Cycle and Margins Assess Recruit Holdings through Indeed, global hiring demand, revenue per customer, matching efficiency, margins and foreign exchange.
  8. Chugai Pharmaceutical · 4519 Chugai Pharmaceutical (4519) Stock: Royalties, Pipeline and 2026 H1 Results Assess Chugai Pharmaceutical through product sales, royalties, one-time income, core operating profit and clinical pipeline risk.
  9. East Japan Railway · 9020 JR East (9020) Stock: Fare Changes, Inbound Travel and Property Earnings Assess JR East through commuter and Shinkansen demand, fare changes, station retail, hotels, property profit, costs and capital spending.
  10. Kioxia Holdings · 285A Kioxia Holdings (285A) Stock: NAND Prices, AI SSD Demand and Capex Risk Assess Kioxia through NAND pricing, shipment volume, AI server SSD demand, inventory, capital spending, free cash flow, debt and litigation.

These articles provide information and research, not recommendations to buy or sell securities. Share prices can change materially, and investors can lose principal.